Clopidogrel pharmacogenomics: Next steps: A clinical algorithm, gene-gene interactions, and an elusive outcomes trial

JACC: Cardiovascular Interventions

Volumn 3, Issue 10, 2010, Pages 995-1000

  Gladding, Patrick ^a,d   Panattoni, Laura ^b   Webster, Mark ^c   Cho, Leslie ^a   Ellis, Stephen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d Theranostics Laboratory   (New Zealand)

Author keywords

clopidogrel; personalized medicine; pharmacogenomics

Indexed keywords

AZATHIOPRINE; CLOPIDOGREL; PRASUGREL; WARFARIN;

ALGORITHM; CLINICAL TRIAL; DRUG DOSE ESCALATION; FOOD AND DRUG ADMINISTRATION; GENE INTERACTION; HUMAN; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ALGORITHMS; BIOTRANSFORMATION; CLINICAL TRIALS AS TOPIC; DRUG LABELING; EVIDENCE-BASED MEDICINE; GENETIC TESTING; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; TICLOPIDINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77958559512     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.08.012     Document Type: Review

References (39)

1. U.S. Food and Drug Administration FDA Drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm March 12, 2010 Accessed September 2010
2. T. Brandt, S. Kirkwood, and N. Mukhopadhyay CYP2C19 (*)2 polymorphism contributes to a diminished pharmacodynamic response to clopidogrel (abstr) J Am Coll Cardiol 47 Suppl 2006 380A
3. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
4. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
5. P. Fontana, J.S. Hulot, P. De Moerloose, and P. Gaussem Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects J Thromb Haemost 5 2007 2153 2155
6. J.T. Brandt, S.L. Close, and S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
7. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
8. K. Umemura, T. Furuta, and K. Kondo The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects J Thromb Haemost 6 2008 1439 1441
9. B.L. Chen, W. Zhang, and Q. Li Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms Clin Exp Pharmacol Physiol 35 2008 904 908
10. L.J. Lesko Paving the critical path: how can clinical pharmacology help achieve the vision? Clin Pharmacol Ther 81 2007 170 177
11. J.R. Powell, and J.V. Gobburu Pharmacometrics at FDA: evolution and impact on decisions Clin Pharmacol Ther 82 2007 97 102
12. Panattoni L, Te Ao B, Brown P, Webster M, Gladding P. Personalised thienopyridine therapy: the cost effectiveness of testing for CYP2C19 variants to guide treatment in patients with acute coronary syndromes. University of Auckland 2010. In press.
13. S.B. Damani, and E.J. Topol The case for routine genotyping in dual-antiplatelet therapy J Am Coll Cardiol 56 2010 109 111
14. J.S. Hulot, J.P. Collet, and J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 (*)2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
15. F. Sofi, B. Giusti, R. Marcucci, A.M. Gori, R. Abbate, and G.F. Gensini Cytochrome P450 2C19( (*))2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 2010 Mar 30 [E-pub ahead of print]
16. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
17. T. Simon, C. Verstuyft, M. Mary-Krause FAST-MI Investigators Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
18. J.P. Collet, J.S. Hulot, and A. Pena L Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
19. D. Sibbing, J. Stegherr, and W. Latz Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
20. B. Giusti, A.M. Gori, and R. Marcucci Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
21. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
22. P. Gladding, H. White, and J. Voss Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study J Am Coll Cardiol Intv 2 2009 1095 1101
23. Y.H. Jeong, S.W. Lee, and B.R. Choi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 2009 1101 1109
24. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
25. T. Cuisset, C. Frere, and J. Quilici Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study J Am Coll Cardiol Intv 1 2008 649 653
26. W. Hochholzer, D. Trenk, and M.F. Fromm Impact of cytochrome P450 2C19 loss-of-function polymorphism and of Major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
27. L. Bonello, S. Armero, and O. Ait Mokhtar Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2 loss of function polymorphism J Am Coll Cardiol 2010 Jul 30 [E-pub ahead of print]
28. P.A. Gurbel, U.S. Tantry, A.R. Shuldiner, and D.J. Kereiakes Genotyping: one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 56 2010 112 116
29. M.D. Caldwell, T. Awad, and J.A. Johnson CYP4F2 genetic variant alters required warfarin dose Blood 111 2008 4106 4112
30. N.S. Ferder, C.S. Eby, and E. Deych Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy J Thromb Haemost 8 2010 95 100
31. M. Wadelius, L.Y. Chen, and K. Downes Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 2005 262 270
32. J. Mega, C. Sandra, and D. Stephen ABCB1 genetic variants, pharmacodynamic response, and cardiovascular outcomes following treatment with clopidogrel and PRASUGREL J Am Coll Cardiol 55 Suppl A 2010 A113
33. N.A. Helsby, W.Y. Lo, and K. Sharples CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype Br J Cancer 99 2008 1251 1255
34. N.A. Helsby Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease Proc West Pharmacol Soc 51 2008 5 10
35. K. Kojima, K. Nagata, T. Matsubara, and Y. Yamazoe Broad but distinct role of pregnane X receptor on the expression of individual cytochrome p450s in human hepatocytes Drug Metab Pharmacokinet 22 2007 276 286
36. G.R. Lichtenstein Use of laboratory testing to guide 6-mercaptopurine/ azathioprine therapy Gastroenterology 127 2004 1558 1564
37. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schomig, and A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 2010 317 318
38. T. Geisler, E. Schaeffeler, and J. Dippon CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation Pharmacogenomics 9 2008 1251 1259
39. J.C. Davis, L. Furstenthal, and A.A. Desai The microeconomics of personalized medicine: today's challenge and tomorrow's promise Nat Rev Drug Discov 8 2009 279 286